Abstract: Disclosed herein a method of constructing a blood vessel map, the method including: receiving, by a blood vessel map construction apparatus, a TOF image of the object; extracting, by the blood vessel map construction apparatus, a blood vessel stem, a center line of a blood vessel, and features of the center line included in the TOF image, and detecting branch points of the blood vessel based on the extracted blood vessel stem, center line of the blood vessel, and features of the center line; searching, by the blood vessel map construction apparatus, a reference blood vessel image corresponding to the TOF image in consideration of location information or curvature information of the branch points; calculating a similarity between the TOF image and the reference blood vessel image; and registering the TOF image in the blood vessel map based on the similarity.

Abstract: A non-aqueous electrolyte solution for a lithium secondary battery and a lithium secondary battery including the same are described herein. Specifically, the non-aqueous electrolyte solution for a lithium secondary battery includes a lithium salt, an organic solvent and a compound represented by Formula 1 to form a robust SEI film, thereby improving battery performance: Wherein R1 to R3 are described herein.

Abstract: An inorganic composite pigment capable of elevating ultraviolet (UV) protection, and a cosmetic composition including the same, in which the inorganic composite pigment includes a core part including a white pigment; and a surface coating material, which is coated on the surface of an external part of the core part, including an inorganic solution that includes the white pigment. Additionally, the white pigment is at least one kind selected from the group consisting of titanium dioxide, zinc oxide, cerium oxide, silica, talc, mica, and borosilicate. The inorganic composite pigment according to the present disclosure capable of elevating a UV protection undergoes surface modification of the pigment through a process of re-coating a white pigment on a white pigment with a high refractive index, thereby elevating the UV protection.

Abstract: An electrolyte additive comprising a compound represented by Formula 1 below forms a coating film on an electrode surface in the activation of a secondary battery, thereby the generation of a large amount of gas under a high temperature condition can be prevented, and a cell OCV drop and a decrease in capacity retention rate, which are caused by elution of metal ions from an electrode, can be effectively prevented, resulting in effective improvement in durability, performance and high-temperature safety of the battery, wherein R1, R2, and M are described herein.

Abstract: A method of recovering a solvent including: supplying polymerization reactants including one or more monomers and a solvent to a reactor to obtain a polymer solution; supplying a stream including the polymer solution to a separator to separate an upper discharge stream including the solvent, wherein the solvent is in a gaseous phase, and a lower discharge stream including the polymer solution; heating a divergence stream including a part of the lower discharge stream from the separator by a heating device and refluxing the divergence stream to the separator; supplying a residue stream including a remainder of the lower discharge stream from the separator to a steam stripping process unit; and adjusting a vapor mass fraction of the divergence stream which is refluxed to the separator with a pressure adjustment valve after being heated by the heating device.

Abstract: Provided is a binder for a secondary battery including a copolymer including repeating units of the Chemical Formula 1, Chemical Formula 2, Chemical Formula 3, and Chemical Formula 4 disclosed herein. When the binder for a secondary battery is applied to a negative electrode and a secondary battery, expansion of the negative electrode may be effectively suppressed. Furthermore, the binder for a secondary battery has improved adhesion to effectively suppress exfoliation and desorption of a negative electrode, thereby manufacturing a secondary battery having significantly improved charge/discharge cycle characteristics and battery performance by using the binder.

Abstract: Disclosed herein relates to an electrolyte composition and a lithium secondary battery including the same, wherein the electrolyte composition can not only effectively reduce gas generated during charging and discharging of the lithium secondary battery by including one or more electrolyte additives of a chemical compound represented by Formula 1 or a chemical compound represented by Formula 2, but also has the advantage of strengthening the SEI layer on the electrode surface, thereby improving the storage characteristics and life characteristics at high temperatures.

Abstract: A vehicle configured for container-swapping, includes: a main frame including a pair of drive modules spaced in a forward/backward direction of the vehicle, and a connecting portion extending in the forward/backward direction of the vehicle to connect the pair of drive modules so that a coupling space is formed therebetween; a container module selectively inserted into the coupling space of the main frame; and a coupling portion configured to couple the main frame and the container to each other while the container module is inserted into the coupling space of the main frame, wherein a driving portion operates and moves the main frame so that the container module is inserted into the coupling space of the main frame.

Abstract: An electrolyte composition with improved high temperature safety and a lithium secondary battery including the same is described herein. The electrolyte composition containing a primary additive comprising a compound represented by Formula 1, and specific amount of a secondary additive that contains one or more of cyclic carbonates, can not only reduce the generation of gas during secondary battery charge-discharge, but also improve storage characteristics and the lifespan characteristics under a high temperature condition by strengthening the SEI coating film on the surface of an electrode. wherein all the variables are described herein.

Abstract: A seat for a vehicle, includes a second row center seat and a second row side seat provided on a partition wall positioned rearward of a driver seat, the second row center seat may move leftward or rightward, and an interval between the seats may be increased in a state in which the second row center seat is moved in a right direction away from the second row side seat, which makes it possible to maximally prevent body contact between a passenger in the second row center seat and a passenger in the second row side seat.

Abstract: Disclosed is a cushion tip-up type seat for a vehicle. The cushion tip-up type seat for a vehicle is configured to perform a tip-up function of a cushion part, and to move a seat leftward and rightward to adjust an interval between left and right seats, whereby left and right spacing between occupants seated in the seats is sufficiently secured and the convenience of the occupants is improved.

Abstract: The present disclosure relates to a vehicle rear seat including: a center seat; and side seats located on the left and right of the center seat, wherein, the center seat is capable of protruding by moving the center seat forward with respect to the side seats, and in the state in which the center seat protrudes forward, it is possible to increase an inter-passenger distance so that physical contact between the passenger of the center seat and the passenger of each of the side seats can be prevented as much as possible.

Abstract: A fusion protein comprises an FGF21 mutant protein and an Fc region of an immunoglobulin. The fusion protein exhibits improved pharmacological efficacy, in vivo duration and protein stability. A pharmaceutical composition containing the fusion protein as an active ingredient may be effectively used as a therapeutic agent for diabetes, obesity, dyslipidemia, metabolic syndrome, non-alcoholic fatty liver disease or non-alcoholic steatohepatitis.

Abstract: The present invention provides a fusion protein comprising an FGF21 mutant protein and an Fc region of an immunoglobulin. The fusion protein according to the present invention exhibits improved pharmacological efficacy, in vivo duration and protein stability, and a pharmaceutical composition comprising the fusion protein as an active ingredient may be effectively used as a therapeutic agent for diabetes, obesity, dyslipidemia, metabolic syndrome, non-alcoholic fatty liver disease or non-alcoholic steatohepatitis.

Abstract: A vehicle control apparatus and method for moving and parking a vehicle double-parked around a parked vehicle are provided. The vehicle control apparatus includes a detector that detects departure intention information of the first vehicle and surrounding information of the second vehicle. A vehicle controller controls autonomous movement of the second vehicle and a processor detects a departure intention of the first vehicle based on the departure intention information. A movement plan of the second vehicle is generated based on the surrounding information when departure intention is detected and the vehicle controller moves the second vehicle based on the movement plan.

Abstract: Provided are a fusion protein having a CCL3 variant with improved in vivo persistency, protein stability and pharmacological activity and a use thereof, more particularly, a fusion protein comprising a CCL3 variant and an immunoglobulin Fc region and a use thereof as a therapeutic agent for lymphopenia, cancer or infection, in which an N-terminal amino acid of a wild-type CCL3? or CCL3? is deleted and an amino acid at a specific position is substituted with a different amino acid at the same position of the wild-type CCL3? or CCL3? in the CCL3 variant.

Abstract: An apparatus and a method provide a four-dimensional effect to a driver and/or passengers of a vehicle. The apparatus includes a first vehicle controller that analyzes data of content played in an electronic device, sets four-dimensional effect information and generates vehicle control information for realizing the four-dimensional effect according to the set four-dimensional effect information, and a second vehicle controller that performs vehicle control based on the vehicle control information in consideration of a driving status of a vehicle.

Abstract: A vehicle control apparatus and method for moving and parking a vehicle double-parked around a parked vehicle are provided. The vehicle control apparatus includes a detector that detects departure intention information of the first vehicle and surrounding information of the second vehicle. A vehicle controller controls autonomous movement of the second vehicle and a processor detects a departure intention of the first vehicle based on the departure intention information. A movement plan of the second vehicle is generated based on the surrounding information when departure intention is detected and the vehicle controller moves the second vehicle based on the movement plan.

Abstract: Provided are a fusion protein having a CCL3 variant with improved in vivo persistency, protein stability and pharmacological activity and a use thereof, more particularly, a fusion protein comprising a CCL3 variant and an immunoglobulin Fc region and a use thereof as a therapeutic agent for lymphopenia, cancer or infection, in which an N-terminal amino acid of a wild-type CCL3? or CCL3? is deleted and an amino acid at a specific position is substituted with a different amino acid at the same position of the wild-type CCL3? or CCL3? in the CCL3 variant.

Abstract: The present invention provides a fusion protein comprising an FGF21 mutant protein and an Fc region of an immunoglobulin. The fusion protein according to the present invention exhibits improved pharmacological efficacy, in vivo duration and protein stability, and a pharmaceutical composition comprising the fusion protein as an active ingredient may be effectively used as a therapeutic agent for diabetes, obesity, dyslipidemia, metabolic syndrome, non-alcoholic fatty liver disease or non-alcoholic steatohepatitis.